Arthur D. Little Reviews 100 Mobility Systems Worldwide in the Third Edition of Its Future of Mobility Study and Updated Urban Mobility Index
Arthur D. Little today released the third edition of its Future of Mobility study, including an updated version of its Urban Mobility Index, which ranks 100 global cities based on the maturity, innovativeness and performance of their urban mobility systems. The study, “The Future of Mobility 3.0 – Reinventing mobility in the era of disruption and creativity”, was launched at the UITP Asia-Pacific Assembly in Taipei.
The Urban Mobility Index found that the majority of cities analyzed still had major potential for improvement to cope with the mobility challenges ahead, with an average score of 42.3 out of a possible 100 points. Singapore led the way (59.3 points), ahead of Stockholm (57.1), Amsterdam (56.7), Copenhagen (54.6) and Hong Kong (54.2). Only 10 cities scored more than 50 points, out of which eight were European and two Asian.
“More than ever, the reform of mobility systems is one of the key challenges facing the world today,” said François-Joseph Van Audenhove, Partner at Arthur D. Little and head of the Future of Mobility Lab. “In order to stay competitive in the short term and relevant in the long term, mobility solutions providers must anticipate new trends, innovate their offerings and differentiate themselves. To achieve this, they should participate in extended ecosystems and embark on transformation journeys.”
With the support of its partner, the International Union of Public Transport (UITP), Arthur D. Little has set out 12 strategic imperatives for mobility solution providers to consider when defining their visions and strategies if they want to remain competitive in the short term and relevant in the long term within extended mobility ecosystems.
“It is at the time when public transport is given new opportunities to grow and expand, that it is also being challenged by the emergence of new actors and technologies enabled by the digital economy,” noted UITP Secretary General Mohamed Mezghani. “Arthur D. Little’s Future of Mobility 3.0 study provides useful references to support the sector in addressing these challenges.”
A copy of the study can be downloaded from www.adl.com/futuremobilitylab.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Quadient Announces General Availability of Quadient Inspire R1225.6.2018 17:30 | Tiedote
www.quadient.com : Quadient, the award-winning leader in Customer Communications Management (CCM), announced the general availability of its newest release, Quadient Inspire R12, which includes the new Digital Advantage Suite. The updated version of Quadient Inspire is designed to give customers and partners greater control over the systems and processes used to drive consistent communications across all channels with an emphasis on digital experiences. With Inspire R12, users design omni-channel communications in days rather than months with a simple, modern and comprehensive platform. The solution makes it possible to change designs and test for all channels in minutes, with fully integrated tracking and approval processes built in. Additionally, R12 integrates all parts of the communications process from linking journey maps to communications, postal sorting, address, phone and email verifications, email delivery, SMS delivery, mail delivery tracking, and production monitoring to re
The Dementia Discovery Fund Raises $350 Million25.6.2018 16:00 | Tiedote
The Dementia Discovery Fund (DDF) today announces the completion of its fundraising, with £250 million ($350 million at the time of completion) raised from an influential group of strategic investors committed to developing new medicines for dementia. The goal was met today with a new investment of $60 million from US AARP, the global nonpartisan organisation dedicated to empowering Americans 50 and older to choose how they live as they age. The fundraising far exceeded its initial target of $200 million (£130 million), making it the first and largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease. The DDF makes early stage venture capital investments to develop novel disease-modifying therapeutics for all forms of dementia. The fund is managed by SV Health and was formed through the collaboration of leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and
Professor Thierry Philip Takes Office as OECI President25.6.2018 15:22 | Tiedote
Professor Thierry Philip, President of the Institut Curie, has been elected President of the Organisation of European Cancer Institutes ( OECI ) for a three-year term. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005600/en/ Pr Thierry Philip (Photo: Business Wire) At the end of June 2018, Professor Philip, an oncologist and pediatrician, will take over as head of this European organization, which brings together 90 institutes and university centers and whose mission is fully devoted to cancer. This European non-governmental, non-profit organization aims to promote cooperation between its members or associate members and pursues a triple objective: to provide cancer patients in Europe with equal access to high-quality care; to assist European institutes with the implementation of a quality system for oncology care; to promote and accelerate the progress of translational research. In this regard, half of the 90 OECI ce
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes25.6.2018 15:07 | Tiedote
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, defined in both trials as placebo-corrected change from baseline in HbA1c after 26 weeks of treatment, was met for all investigated doses of empagliflozin (2.5, 10, and 25 mg). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005579/en/ Type 1 diabetes currently affects approximately 30 million adults worldwide.1 It is an autoimmune disease in which the body does not produce sufficient amounts of insulin and therefore requires life-long daily insulin administration to regulate blood sugar. For some people with type 1 diabetes, it may be challenging to manage blood sugar levels with insulin alone. People with type
European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection25.6.2018 15:03 | Tiedote
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the European Commission has granted Marketing Authorization for Biktarvy® (bictegravir 50mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg; BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. BIC/FTC/TAF combines the potency of the novel integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg; FTC/TAF), a guidelines-recommended dual nucleoside reverse transcriptase inhibitor (NRTI) backbone. Today’s decision makes BIC/FTC/TAF Gilead’s third FTC/TAF-based STR approved in the European Union in the past three years. In Europe, BIC/FTC/TAF is indicated as a complete regimen for the treatment of HIV-1 infection in adults without present or past evidence of viral resistance to the integrase class, emtricitabine or tenofovir. No dosage adjustment of BIC/FTC/TAF is required in patien
AlipayHK and GCash Launch Cross-Border Remittance Service Powered by Alipay’s Blockchain Technology25.6.2018 15:00 | Tiedote
AlipayHK and GCash today announced the launch of a cross-border remittance service through their e-wallet platforms, powered by cutting-edge blockchain technology developed by Alipay, the online payment platform operated by Ant Financial Services Group (“Ant Financial”, “Ant”). This is the first blockchain-based cross-border digital wallet remittance service globally, offering a fast, secure, convenient, transparent and low-cost way to transfer money directly between individuals in Hong Kong and the Philippines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005561/en/ Mary Grace (left), who has been working in HK for 22 years, demonstrated how it took her 3 seconds to transfer money to her family back in the Philippines, through the mobile payment app AlipayHK (Photo: Business Wire) Alipay has applied blockchain technology to streamline the remittance process, radically improving the speed of delivery, enhancing trans
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme